Orion: Phase III Trial With Darolutamide Meets Primary Endpoint In MHSPC

Orion Oyj announced Orion's and Bayer's (BAYZF.PK,BAYRY.PK,BYR.L) phase III ARASENS trial showed an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy compared to docetaxel and androgen deprivation therapy, a standard of care in metastatic hormone-sensitive prostate cancer. The overall incidence of reported adverse events was similar between treatment arms, the company said.

Bayer plans to discuss the data from ARASENS with health authorities worldwide regarding the submission for marketing authorisation in this indication.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT